FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for PolyPid in a research note issued on Monday, December 16th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($4.83) per share for the year, down from their prior estimate of ($4.39). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($2.41) EPS.

Separately, Craig Hallum assumed coverage on PolyPid in a research note on Monday, November 4th. They set a “buy” rating and a $10.00 target price for the company.

PolyPid Price Performance

Shares of NASDAQ PYPD opened at $3.50 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. PolyPid has a fifty-two week low of $2.37 and a fifty-two week high of $9.20. The business has a 50 day moving average price of $3.29 and a two-hundred day moving average price of $3.57. The firm has a market cap of $16.79 million, a PE ratio of -0.45 and a beta of 1.33.

Hedge Funds Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Stonepine Capital Management LLC acquired a new position in PolyPid Ltd. (NASDAQ:PYPD) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned 2.89% of PolyPid as of its most recent SEC filing. 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.